Deep Enhanced Imaging in Stroke and Vascular Neurology
Launched by CHINESE PLA GENERAL HOSPITAL · Nov 5, 2022
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into a new imaging technique called deep enhanced imaging to see how it performs compared to traditional CT or MRI scans for patients who may have had a stroke or other vascular issues in the brain. The goal is to see if this advanced imaging can provide better quality pictures, reduce the time needed for imaging, and ultimately enhance the care patients receive during their imaging sessions.
To be eligible for this trial, participants should be at least 18 years old and have symptoms suggesting they might have had a stroke or other brain issues that require imaging. They also must not have a history of kidney failure and must be able to provide written consent to participate. Unfortunately, individuals with certain conditions, like severe movement difficulties or a history of brain tumors, cannot join. If you participate, you can expect to undergo brain imaging using this new technique and help researchers understand how it might improve care for stroke patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • suspecting to have experienced stroke or cerebral ischemia and needed to undergo brain imaging and vascular imaging including CT or MRI
- • no history of kidney failure
- • a minimum age of 18 years
- • obtained written informed consent
- Exclusion Criteria:
- • severe movement artifacts
- • incidental finding of tumor lesion or craniocerebral surgery history
- • poor imaging failed to perform deep learning method
- • women who pregnancy
About Chinese Pla General Hospital
The Chinese PLA General Hospital, a prominent military medical institution in Beijing, serves as a leading sponsor for clinical trials, focusing on advancing healthcare through innovative research and development. Renowned for its comprehensive medical services and cutting-edge research capabilities, the hospital is committed to improving patient outcomes through rigorous scientific investigation and collaboration with various stakeholders in the healthcare sector. With a multidisciplinary approach and a strong emphasis on evidence-based practices, the Chinese PLA General Hospital aims to contribute significantly to the global medical community by facilitating the development of safe and effective therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Lou Xin
Study Chair
Chinese PLA General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials